Congresswoman Anna Paulina Luna, a member of the Republican Party serving Florida's 13th congressional district, recently embarked on her first foray into stock trading as a lawmaker. Her investment of up to $15,000 was made in LineageCell, a biotech company, on January 2nd, 2024.
This strategic investment occurred shortly before LineageCell announced encouraging outcomes from their Phase 1/2a clinical trial. The study focused on OpRegen, a novel cell therapy designed to treat age-related macular degeneration, a significant cause of vision loss.
LineageCell Therapeutics ($LCTX) is a pioneering biotechnology firm specializing in regenerative medicine and cell therapy. Known for its innovative approach, the company focuses on developing treatments for conditions that currently have limited therapeutic options.
Their notable work includes groundbreaking research in age-related macular degeneration, a leading cause of vision loss. LineageCell's dedication to advancing cell therapy technology positions it as a key player in the biotech industry.
Subscribe to our newsletter!
By submitting your email, you agree to our Terms of Service and Privacy Notice. You can opt out at any time.
Subscribe to our newsletter!
By submitting your email, you agree to our Terms of Service and Privacy Notice. You can opt out at any time.
By submitting your email, you agree to our Terms of Service and Privacy Notice. You can opt out at any time.